11:55 AM EST - MethylGene Inc. : reported second-quarter net loss of $6.92 million or $0.19 per share, compared to net loss of $7.4 million or $0.20 per share last year. Total revenues were $388,000, compared to $4.3 million in the same period last year. This reduction in revenue was primarily due to the termination of our collaboration agreement with Celgene Corporation which was partially offset by revenues from our collaboration with Otsuka Pharmaceutical Co. Ltd. MethylGene Inc.
shares T.MYG are trading $0.015 at $0.25.
